top of page

Lorlatinib

Lorlatinib is a 3rd generation TKI developed by Pfizer.  In England, Wales and Northern Ireland it is licensed for use after progression on a 2nd generation TKI.  In Scotland, it is also licensed for 1st line treatment.  The recommended dose is 100mg taken daily.

New

Anyone with lungs can get lung cancer.

bottom of page